Cargando…
In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430561/ https://www.ncbi.nlm.nih.gov/pubmed/35758747 http://dx.doi.org/10.1128/spectrum.01724-22 |
_version_ | 1784779805966729216 |
---|---|
author | Karlowsky, James A. Walkty, Andrew J. Baxter, Melanie R. Adam, Heather J. Lagacé-Wiens, Philippe R. S. Schweizer, Frank Bay, Denice Lynch, Joseph P. Mulvey, Michael R. Zhanel, George G. |
author_facet | Karlowsky, James A. Walkty, Andrew J. Baxter, Melanie R. Adam, Heather J. Lagacé-Wiens, Philippe R. S. Schweizer, Frank Bay, Denice Lynch, Joseph P. Mulvey, Michael R. Zhanel, George G. |
author_sort | Karlowsky, James A. |
collection | PubMed |
description | Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR) (n = 235) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. Most isolates testing not susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam remained susceptible to cefiderocol. In vitro data suggest that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. IMPORTANCE After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. |
format | Online Article Text |
id | pubmed-9430561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-94305612022-09-01 In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 Karlowsky, James A. Walkty, Andrew J. Baxter, Melanie R. Adam, Heather J. Lagacé-Wiens, Philippe R. S. Schweizer, Frank Bay, Denice Lynch, Joseph P. Mulvey, Michael R. Zhanel, George G. Microbiol Spectr Observation Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR) (n = 235) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. Most isolates testing not susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam remained susceptible to cefiderocol. In vitro data suggest that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. IMPORTANCE After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. American Society for Microbiology 2022-06-27 /pmc/articles/PMC9430561/ /pubmed/35758747 http://dx.doi.org/10.1128/spectrum.01724-22 Text en Copyright © 2022 Karlowsky et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Observation Karlowsky, James A. Walkty, Andrew J. Baxter, Melanie R. Adam, Heather J. Lagacé-Wiens, Philippe R. S. Schweizer, Frank Bay, Denice Lynch, Joseph P. Mulvey, Michael R. Zhanel, George G. In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title | In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title_full | In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title_fullStr | In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title_full_unstemmed | In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title_short | In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019 |
title_sort | in vitro activity of cefiderocol against extensively drug-resistant pseudomonas aeruginosa: canward, 2007 to 2019 |
topic | Observation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430561/ https://www.ncbi.nlm.nih.gov/pubmed/35758747 http://dx.doi.org/10.1128/spectrum.01724-22 |
work_keys_str_mv | AT karlowskyjamesa invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT walktyandrewj invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT baxtermelanier invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT adamheatherj invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT lagacewiensphilippers invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT schweizerfrank invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT baydenice invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT lynchjosephp invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT mulveymichaelr invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 AT zhanelgeorgeg invitroactivityofcefiderocolagainstextensivelydrugresistantpseudomonasaeruginosacanward2007to2019 |